From SharePoint Keywords to 9X Search Accuracy: How Enterprise AI Is Transforming Global Biopharma Product Development

Global biopharmaceutical product development is one of the most information-intensive processes in any industry. A single drug program moving from discovery through Phase III generates millions of documents — study protocols, lab notebooks, safety data, clinical study reports, regulatory correspondence, manufacturing records, and the accumulated scientific output of hundreds of researchers working across years and geographies. The decisions that determine whether that program succeeds — compound selection, trial design, regulatory strategy, market application — all depend on access to the right information at the right moment.

For most large biopharma organizations, that access is far more limited than it should be.

This post examines how one global biopharmaceutical leader — tens of thousands of employees, global R&D operations, and hundreds of millions of documents in its product development knowledge base — transformed its information access infrastructure with enterprise AI, and what the results reveal about the product development intelligence challenge facing the broader biopharma industry.

The Problem: Keyword Search Across 500 Million Documents

The company’s situation before deployment was not unusual. It was running product development information access on an outdated SharePoint environment with basic keyword search capabilities. Staff searched for information using simple keyword queries, with no semantic understanding of query intent, no cross-system retrieval, and no guarantees that the most relevant content was actually surfacing — only that documents containing the search terms were being returned.

In a standard enterprise context, this limitation is a productivity problem. In a biopharma product development context, it is a strategic risk.

The volume of relevant content is too large for manual navigation: the company had approximately 500 million documents indexed across its knowledge base. The diversity of content types is too great for keyword matching alone to handle: scientific literature, clinical data, regulatory submissions, manufacturing specifications, patent records, and internal research reports all require semantic understanding to retrieve relevantly. And the stakes of a missed result are too high to accept the failure modes of keyword search — a relevant prior study not surfaced during trial design, a regulatory precedent missed in submission preparation, a safety signal not connected to prior documentation.

The company’s solution engineering lead identified the need for enterprise AI search capable of meeting these requirements and began evaluating platforms accordingly.

What Enterprise AI Search Required in This Context

The requirements the company’s internal stakeholders defined went beyond basic search improvement. They needed a platform that could automatically classify and tag content across diverse source types, provide semantic indexing that understood scientific and clinical terminology, support granular filtering by content type, therapeutic area, study status, and other biopharma-relevant dimensions, and handle the integration of new data sources as the organization’s information environment evolved.

Critically, they needed access controls robust enough for a regulated industry environment — ensuring that users accessed only the information they were authorized to view, with the security confidence required for clinical and regulatory content. The deployment experience revealed how important this requirement was: once enterprise AI search was in place, employees were surfacing so much more relevant content that they began to worry they were accidentally accessing information beyond their authorization level. The organization had to add a security assurance message to the interface — confirmation that the system was enforcing access controls correctly and that users were only seeing what they were permitted to see.

This is a revealing detail. It says two things simultaneously: the platform was dramatically more effective at surfacing relevant content than the previous system, and the access control architecture was sound enough that the concern could be definitively addressed by the system’s own design.

The Results: 9X Improvement in Findability and Accuracy

Following deployment of Sinequa’s enterprise agentic AI platform, the company achieved:

9X improvement in information findability and accuracy. This is not a marginal gain — it is a step-change in the fundamental capability that drives product development decision quality. Researchers, regulatory specialists, and clinical teams working on product development programs were finding the right information nine times more reliably than they had with keyword search.

5% improvement in staff information search efficiency. Across an organization with tens of thousands of employees each searching for information multiple times daily, a 5% efficiency improvement compounds into a very significant reduction in aggregate time spent on information retrieval rather than on the scientific and clinical work that actually advances drug programs.

500 million documents indexed and searchable. The full knowledge base — not a curated subset, not the most recent documentation, but the complete accumulated product development knowledge of a global organization — became accessible through a unified, semantically intelligent search interface.

The Biostatistician Breakthrough: Beyond Metadata Search

One of the most technically significant outcomes of the deployment reveals a capability gap that is common across biopharma organizations but rarely discussed explicitly: the inability to search clinical data beyond metadata.

Before the deployment, the company’s biostatisticians could search the metadata of SAS datasets — the index of what the data contained — but not the data itself. This meant that when biostatisticians needed to identify patient populations across multiple trials for a specific disease criterion, or when they needed to analyze dosing patterns across multiple studies to inform a new trial protocol, they were effectively limited to what the metadata summaries described rather than what the data actually showed.

Advanced RAG capabilities changed this. Biostatisticians gained the ability to search across hundreds of patient criteria per patient record, across the actual clinical data rather than its metadata description. The implications for product development are substantial: protocol designers working with actual cross-trial patient data rather than metadata summaries can design more precise inclusion and exclusion criteria, identify eligible patient populations more efficiently, and build evidence-driven trial designs grounded in the full depth of the organization’s clinical experience.

This is exactly the kind of compound intelligence — where access to clinical history across multiple programs informs the design of the next program — that is theoretically available to every large biopharma organization with an extensive trial history, but practically unavailable when data access is limited to metadata queries.

What This Means for Global Biopharma Product Development

This case study illustrates a broader dynamic in biopharma product development that organizations across the industry are navigating: the gap between the extraordinary depth of scientific and clinical knowledge that large biopharma organizations accumulate, and the fraction of that knowledge that is practically accessible to the people making product development decisions.

For product development specifically, the value concentrates in three areas:

Faster, better-informed trial design. Protocol designers with access to the full cross-trial clinical history of their organization design more precise, evidence-grounded protocols — with better-targeted patient populations, more informed dosing rationale, and stronger awareness of prior safety signals that should inform the new study design.

More effective regulatory preparation. Regulatory teams preparing submissions or responding to agency queries with access to the full prior submission history, agency correspondence, and scientific evidence base from related programs produce stronger submissions — with better-anticipated agency questions and more complete supporting documentation.

Reduced duplication of scientific effort. Researchers with access to the full body of internal scientific knowledge are less likely to reproduce experiments already completed, pursue compound directions already ruled out, or miss prior findings that would have redirected their current work.

The Deployment Architecture That Made It Work

The deployment in this case study succeeded because it addressed the technical requirements of biopharma product development environments specifically — not generic enterprise search requirements adapted for life sciences.

The platform connected to the organization’s full content environment, not a curated subset. It provided semantic understanding of scientific and clinical terminology, not just keyword indexing. It enforced access controls at the retrieval layer, meeting the information governance requirements of a regulated industry. And it supported the extension of search to structured clinical data — the SAS dataset capability that gave biostatisticians access to actual patient-level data across trials.

These are the architectural requirements that determine whether an enterprise AI platform generates results like the ones documented above, or whether it delivers a marginal improvement on keyword search in a more modern interface.

For biopharma product development leaders evaluating AI platforms, the relevant evaluation criteria mirror what this company required: semantic scientific search quality, cross-system data coverage including structured clinical data, retrieval-layer access control, and the ability to extend the platform to new use cases as the organization’s AI maturity develops.